Although OnabotulinumtoxinA (Botox) is the only drug licensed for chronic migraine (CM) prevention, but its efficacy with analgesic overuse was still undermanaged. Hence, to know about CM with medication overuse, this study was employed which revealed beneficial results.

To review the evidence of efficacy of OnabotulinumtoxinA (Botox) in chronic migraine (CM) with and without medication overuse, its limitations and key findings from prospective data from a tertiary headache clinic. CM is a disabling neurological condition, affecting around 2% of the general population with significant impact on quality of life and ability to work and perform activities of daily living. Botox is the only medication licensed for CM prevention. Its safety and efficacy has been shown in randomized controlled trial PREEMPT. However, it remains debatable as to whether patients with CM and analgesic overuse be subjected to withdrawal of overused medication before commencing preventive treatment.

Patients that attended the Hull Migraine Clinic and received OnabotulinumtoxinA for chronic migraine were included. The patients were dived in those with and without medication overuse based on the International Headache Criteria. The data was collected through a dedicated headache diary.

The Hull Migraine Clinic provides prospective real-life data on patients with CM treated with OnabotulinumtoxinA (Botox).

The data showed OnabotulinumtoxinA (Botox) to be equally effective in CM patients with and without medication overuse.